May 22nd 2025
Itovebi plus Ibrance and Faslodex improved overall survival in patients with PIK3CA-mutant, HR+, HER2–, endocrine-resistant breast cancer versus placebo.
May 22nd 2025
May 21st 2025
May 19th 2025
March 10th 2025
March 7th 2025
March 6th 2025
March 5th 2025